Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2024-03-20 Annual Report
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 70th fiscal year (2023), covering the period from 2023-01-01 to 2023-12-31. It is addressed to the Financial Services Commission and the Korea Exchange. This is a standard Korean Annual Report (10-K equivalent), containing detailed company information, business operations, financial data, and management discussions. FY 2023
2024-03-20 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samsung Pharmaceutical. It outlines the date, location, and agenda items (approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2024-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding a significant change in sales or profit/loss structure (30% or more). It provides preliminary financial data (revenue, operating profit, net income) comparing the current fiscal year to the previous one. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for listed companies to announce material financial changes before the final audit report is filed. It fits the 'Earnings Release' (ER) category as it provides key financial highlights and reasons for the changes. FY 2023
2024-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Samsung Pharmaceutical Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information such as director activities and financial statements for the 70th fiscal year. This document is a standard proxy statement/notice sent to shareholders to inform them of the upcoming AGM and request their participation/votes, which aligns with the 'Proxy Solicitation & Information Statement' category.
2024-03-13 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting, agenda items (approval of financial statements, election of directors, remuneration limits), and proxy solicitation procedures. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-13 Korean
투자판단관련주요경영사항 (알츠하이머병 치료제로서 GV 1001의 국내 제3상 임상시험계획 변경승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding a change in the clinical trial plan for an Alzheimer's drug (GV1001). It is a formal disclosure of a material business event (major management matter) submitted to the Korea Exchange (KRX). Since it details a specific regulatory approval for a clinical trial and does not fit into categories like financial reports, dividends, or shareholder meetings, it is classified as a general regulatory filing.
2024-03-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.